A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Imsidolimab (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Acronyms ACORN
- Sponsors AnaptysBio
- 14 Mar 2022 According to an AnaptysBio media release, company discontinue imsidolimab clinical development in acne.
- 14 Mar 2022 Status changed from recruiting to discontinued, according to an AnaptysBio media release.
- 14 Mar 2022 According to an AnaptysBio media release, primary endpoint (To determine the effect of Imsidolimab compared with placebo change from baseline in facial inflammatory lesion count at week 12.) has not been met.